Literature DB >> 1982449

Impairment of cell-mediated immune responses in HTLV-I-associated myelopathy.

Y Kuroda1, H Takashima.   

Abstract

In order to assess in vivo cell-mediated immune functions in HTLV-I-associated myelopathy (HAM), we immunized 18 HAM patients with dinitrochlorobenzene (DNCB). Of 18 patients, the skin reaction to DNCB was negative in 15. All those 15 patients also showed anergy to PPD-tuberculin and 9 of 15 patients had a persistent lymphocytopenia (less than 1500/mm3). In vitro lymphoproliferative responses to mitogens, assayed by a flow fluorocytometric method, were also significantly depressed in HAM patients when compared to normal controls. The results thus indicate that cell-mediated immune functions are significantly impaired in HAM patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982449     DOI: 10.1016/0022-510x(90)90035-l

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens.

Authors:  Rita Elizabeth Mascarenhas; Cláudia Brodskyn; Geisa Barbosa; Jorge Clarêncio; Antônio Souza Andrade-Filho; Frederico Figueiroa; Bernardo Galvão-Castro; Fernanda Grassi
Journal:  Clin Vaccine Immunol       Date:  2006-05

2.  Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin.

Authors:  Y Kuroda; H Takashima; A Ikeda; C Endo; R Neshige; R Kakigi; H Shibasaki
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

3.  Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model.

Authors:  Rashade A H Haynes; Evan Ware; Christopher Premanandan; Bevin Zimmerman; Lianbo Yu; Andrew J Phipps; Michael D Lairmore
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

4.  Reduction of human T-cell leukemia virus type 1 (HTLV-1) proviral loads in rats orally infected with HTLV-1 by reimmunization with HTLV-1-infected cells.

Authors:  Kazuya Komori; Atsuhiko Hasegawa; Kiyoshi Kurihara; Takayuki Honda; Hiroo Yokozeki; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Association Between HTLV-I Infection with Chronic Lupoid Leishmaniasis.

Authors:  Fakhrozaman Pezeshkpoor; Seyed Abdol Rahim Rezaei; Abbas Shirdel; Mohammad Khajedaluee; Mansoreh Alizadeh; Mohammad Javad Yazdanpanah
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

6.  Cutaneous Manifestations in HTLV-I Positive Blood Donors.

Authors:  Mohammad Javad Yazdanpanah; Masoud Maleki; Nasaibe Joneidi; Amir Reza Khalighi; Mahmoud Reza Azarpazhooh; Mohammad Khajedaluee; Farahnaz Tehranian; Majid Shahabi; Mohammad Esmaeil Khayami; Fatemeh Livani
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.